Hormonal contraception and HIV risk: A review

By Rebecca Bowers

This article originally appeared in the August 2007 issue of Contraceptive Technology Update. It was written by Rebecca Bowers, and edited by Joy Dickinson. Both Rebecca Bowers and Joy Dickinson report no financial relationships relevant to this field of study.

Results from past research studies have investigated a possible relationship between hormonal contraceptive use and HIV acquisition, but understanding remained poor due to inconsistent results and shortfalls in study design.1 A 2007 multinational prospective cohort study found no overall statistically significant association between the use of combined oral contraceptive (COC) pills or depot medroxyprogesterone acetate (DMPA) and HIV acquisition.2 (Contraceptive Technology Update reported on the study; see the article, "Hormonal contraception use doesn't up HIV risk," March 2007, p. 29.)

A total of 6,109 women participated in the study: 2,235 in Uganda, 2,296 in Zimbabwe, and 1,578 in Thailand. All were family planning clinic clients. At the time of enrollment, the women were using no hormonal contraception, or they had used COCs or DMPA for at least three months before the study began. Women who were not using hormonal contraception used such methods as condoms alone, diaphragms and spermicides, sterilization, withdrawal, or periodic abstinence, or they used no birth control method.

In the study, the women were offered their choice of oral contraceptives or DMPA, as well as condoms. Researchers counseled women on how to use their chosen methods, as well as how to reduce their risk of HIV infection. Women also were examined for sexually transmitted infections and offered treatment if needed. HIV tests were administered four to five times a year for 15 to 24 months.

By the study's end, 213 African women had become infected with HIV, while only four Thai women were identified with the infection. Since there were too few Thai cases for a valid statistical interpretation, the researchers excluded them from the final analysis.

The researchers report that neither COCs [hazard ratio (HR), 0.99; 95% confidence interval (CI), 0.69-1.42] nor DMPA (HR, 1.25; 95% CI, 0.89-1.78) was associated with risk of HIV acquisition overall, including among participants with cervical or vaginal infections. While absolute risk of HIV acquisition was higher among participants who were seropositive for herpes simplex virus 2 (HSV-2) than in those seronegative at enrollment, among the HSV-2-seronegative participants, both combined pill users (HR, 2.85; 95% CI, 1.39-5.82) and DMPA users (HR, 3.97; 95% CI, 1.98-8.00) had an increased risk of HIV acquisition compared with the nonhormonal group.

The subgroup of women who were not infected with genital herpes at enrollment comprised about half the women in the study. Among this subgroup, those women who used hormonal contraceptive methods had an increased HIV infection risk, as shown in the statistics above: Combined pill users had almost three times and DMPA users had four times the risk of acquiring HIV when compared to women not using hormonal contraceptives.

"Among women who are HSV-2-negative, DMPA and COC users may be at increased risk of HIV acquisition," concluded the researchers in their analysis. "Additional research should confirm and interpret this finding."

Neither the World Health Organization nor the International Planned Parenthood Federation, which reviewed the study results, plans at this time to change guidelines for hormonal contraceptive use.1

Counsel on condoms

Researchers continue to look at linkages between combined pill use and increased sexually transmitted infection (STI) risk. Findings suggest that combined pills influence transcription of natural antimicrobials in the human endometrium, which may increase a woman's vulnerability to upper-tract chlamydia or HIV infection.3

In the same vein, DMPA provides no protection against STIs, including HIV. Several observational studies have shown an association between DMPA use and acquisition of chlamydia.4-6 In two studies, DMPA use has been inconsistently associated with acquisition of gonorrhea.4,6 Studies in high-risk populations, including sex workers in Kenya and Thailand, have demonstrated an association between DMPA and HIV acquisition,7,8 while other research has not observed an association.9

What does this mean for family planning clinicians? Because hormonal contraception does not protect against HIV, women who use hormonal contraception and are at elevated risk of acquiring HIV also should use condoms consistently and correctly with each sexual act if they are not in a mutually monogamous relationship with an uninfected partner.1 Advice from the current edition of Contraceptive Technology says it best: "To reduce risks for STIs, women should choose to be sexually active with one uninfected, monogamous partner or, at a minimum, use latex or polyurethane condoms with every act of vaginal or rectal intercourse and should consider condom use with oral-genital contact, too."10

References

  1. Best K. Hormonal contraception and HIV: More research needed; no changes in family planning practices currently warranted. Global Health Technical Briefs; accessed at: www.maqweb.org/techbriefs/tb23hormonal.pdf.
  2. Morrison CS, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95.
  3. Fleming DC, et al. Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril 2003; 79:856-863.
  4. Baeten J, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. Am J Obstet Gynecol 2001; 185:380-385.
  5. Jacobson D, et al. Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents. Sex Transm Dis 1999; 27:313-319.
  6. Morrison C, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis 2004; 31:561-567.
  7. Martin HL Jr., et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178:1,053-1,059.
  8. Ungchusak K, et al. Determinants of HIV infection among female commercial sex workers in northeastern Thailand: Results from a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:500-507.
  9. Bulterys M, et al. Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS 1994; 8:1,585-1,591.
  10. Hatcher RA, et al. Contraceptive Technology: 19th revised edition. New York City: Ardent Media; 2007.